Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines

J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2456-2461. doi: 10.1111/jdv.17633. Epub 2021 Sep 16.

Abstract

Background: Cutaneous reactions, mostly on injection site after mRNA-based COVID-19 vaccines, have been reported but not with detailed histopathological characterization.

Objectives: Characterization and classification of these reactions in a clinical and pathological point of view.

Methods: Monocentric case series of 11 patients with cutaneous manifestations, clinically and histologically characterized after COVID-19 vaccination.

Results: From January to June 2021, we recorded 11 cutaneous reactions to mRNA COVID-19 vaccines from BNT162b2 (n = 8) and mRNA-1273 (n = 3). Generalized reactions showing erythematous rash or purpura were the most common clinical presentation, and drug-reaction-like pattern was the most common histological finding.

Conclusions: A proper clinicopathological classification will be helpful in the early diagnosis and management of the cutaneous reactions to mRNA COVID-19 vaccines.

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines*
  • COVID-19*
  • Humans
  • RNA, Messenger
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • BNT162 Vaccine